1 min read

Intermountain, UT Health, Rush U Joins physIQ’s COVID-19 Digital Biomarker Study

Originally published in HIT Consultant

What You Should Know:

– Today,  physIQ announced that three more health systems have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. Intermountain Healthcare Utah, The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center will serve as recruiting centers and key partners in the Phase II validation stage of this study.

– Realization of this biomarker may provide early detection of a rapid clinical decompensation in high-risk COVID-19 positive patients. The DeCODe study, along with other physIQ-led projects, is helping to identify the earliest signals of an inflammatory response specific to an individual who may have COVID.

– As a result of DeCODe’s Phase I success, physIQ was able to apply for a portion of the $1.5 million federal government initiative to study COVID-19 patients with long-term symptoms (also known as long haulers). Because of the vast enrollment numbers of COVID-19 patients in the DeCODe study, there is a high likelihood that some are long-haulers.  Intermountain, UTHealth and Rush will also partner with physIQ on this study.